Concepedia

Author

Hajir Ibraheim

Imperial College LondonORCID

Also Known As

H A Ibraheim, H Ibraheim, H. Ibraheim, Hajir Ibraheim, Ibraheim Hajir, Leon R. McFarlane, Sharmili Balarajah

75

Publications

1.1K

Citations

16

H-Index

16

Concepts

All Affiliations

Imperial College LondonKing's College LondonGuy's and St Thomas' NHS Foundation TrustUniversity of HullUniversity of Exeter
HI

About

Hajir Ibraheim is an author at Imperial College London specializing in inflammation, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

39

2

Gastroenterology

2

2

39

3

Immunology

2

2

39

4

Pathology

2

2

39

5

Allergy

1

1

10

Hajir Ibraheim

×

12

Publications

668

Citations

11

H-Index

YearCitations

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti,

Journal of Clinical Oncology

2019

188

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study

James L. Alexander, Nicholas A. Kennedy, Hajir Ibraheim,

˜The œLancet. Gastroenterology & hepatology

2022

147

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study

James L. Alexander, Zhigang Liu, Diana Mūnoz Sandoval,

˜The œLancet. Gastroenterology & hepatology

2022

64

The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients

James L. Alexander, Benjamin H. Mullish, Nathan Danckert,

EBioMedicine

2023

53

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Neil Chanchlani, Simeng Lin, Desmond Chee,

Journal of Crohn s and Colitis

2021

45

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou,

˜The œLancet. Gastroenterology & hepatology

2022

35

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

James L. Alexander, Hajir Ibraheim, Bhavisha Sheth,

Journal for ImmunoTherapy of Cancer

2021

33

775 Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti,

The American Journal of Gastroenterology

2019

29

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience

Hajir Ibraheim

Annals of Gastroenterology

2020

26

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis

Jonathan W. Lo, Domenico Cozzetto, James L. Alexander,

Nature Communications

2023

23

Page 1